Salvage lenalidomide in four rare oncological diseases

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

SZTURZ Petr ADAM Zdeněk REHAK Zdenek KOUKALOVÁ Renata KŘEN Leoš MOULIS Mojmír KREJČÍ Marta MAYER Jiří

Rok publikování 2013
Druh Článek v odborném periodiku
Časopis / Zdroj Tumori
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1377&id=15326
Doi http://dx.doi.org/10.1700/1377.15326
Obor Onkologie a hematologie
Klíčová slova Langerhans cell histiocytosis; Erdheim-Chester disease; angiomatosis; Castleman disease
Popis In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). For disease activity evaluation each patient underwent fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography scan imaging, which was complemented by clinical and laboratory investigations.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.